Skip to main content
Team Jack Foundation - Funding Research for Pediatric Brain Cancer

Follow on    Like on    SHOP   DONATE  

 
 
 

Funding Research for Pediatric Brain Cancer

  • Home
  • About
  • Research
  • Get Involved
    • Fundraise
    • Give
    • Events
    • Become a Sponsor
    • Volunteer
  • Families
 
 

Clinical Trial Finder

Filters

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

You can narrow your results further by searching each trial’s description for a specific word. Keep in mind that this will search the full description. We recommend carefully reviewing each trial information to ensure that it is an appropriate fit for you.

2051 - 2060 of 2066 Trials
  • X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

    In this Phase I trial for subjects with advanced head & neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to establish the safety of X-PACT when dosed with 5 intra-tumoral injections of the combination product (the phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) over a period of 6 weeks (on day D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6). After the week 8 tumor assessment subjects demonstrating stable disease, partial response or...

    18 Years and Over
    Not yet recruiting
    Learn More
  • 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

    This is a compassionate use protocol to allow patients with advanced neuroblastoma palliative access to 131I-metaiodobenzylguanidine (131I-MIBG).

    1 Year and Over
    Available
    Learn More
  • 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

    This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

    N/A and Over
    Available
    Learn More
  • 131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

    Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma cells. MIBG is combined with radioactive iodine (131 I) in the laboratory to form a radioactive compound 131 I-MIBG. This radioactive compound delivers radiation specifically to the cancer cells and causes them to die. The purpose of this research protocol provides a mechanism to deliver MIBG therapy when clinically indicated, but also to provide a mechanism to continue to collect efficacy and toxicity data that will be provided. A recent New Approaches to Neuroblastoma Therapy (NANT) phase 2 randomized trial of 131I-MIBG with or without...

    1 Year and Over
    Available
    Learn More
  • 18F-FDOPA PET in Neuroendocrine Tumours

    Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative. Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.

    1 Month and Over
    Available
    Learn More
  • A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

    This is an expanded access protocol/compassionate use single institution study designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with progressive neuroblastoma and metastatic pheochromocytoma who are not eligible for therapies of higher priority. Response rate, toxicity, and time to progression and death will be evaluated.

    365 Days - 29 Years
    Available
    Learn More
  • An Intermediate Expanded Use Trial of DFMO

    To provide DFMO in an expanded use setting to subjects with relapsed rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase.

    N/A - 30 Years
    Available
    Learn More
  • Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

    The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

    N/A and Over
    Available
    Learn More
  • Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAFmutation-positive Metastatic Melanoma

    The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF mutation-positive.

    1 Year and Over
    Available
    Learn More
  • EAP for the Treatment of Glioblastoma With PVSRIPO

    This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.

    18 Years and Over
    Available
    Learn More
← Previous 1 … 201 202 203 204 205 206 207 Next →
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Team Jack Foundation

PO Box 607, Atkinson, NE 68713

For general information

Info@TeamJackFoundation.org

fundraiser information

Kylie@TeamJackFoundation.Org

media inquiries

Info@TeamJackFoundation.Org

other questions call

855-RUN-JACK

      

About

  • About Us
  • Our Focus
  • Team Jack All Stars
  • Jack Hoffman
  • Team Jack News
  • Team Jack Blog
  • Video Gallery
  • Husker Alumni Chapter

Get Involved

  • Fundraise
  • Give
  • Events
  • Become a Sponsor
  • Volunteer

Shop

  • Team Jack Apparel
  • Team Jack Accessories
  • Team Jack All Stars
  • Clearance Rack

Resources

  • CureSearch.org
  • CureTheKids.org
  • Dana-Farber.org

 
 

Join Our Fight!!!

News, events and research delivered to your inbox.

Committed to helping find a cure for pediatric brain cancer.

© Copyright Team Jack Foundation (All Rights Reserved)

Privacy Policy